FACTORS RELATED TO RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS-RELATED INTESTINAL LUNG DISEASE

U. Kalyoncu1, M. Ekcii2, E. Bilgin3, A. San4, Y. Baytar4, E. C. Bolet4, B. Arman6, B. Farişoğulları7, O. Karadag2, A. I. Ertendi8, S. Kiraz9, L. Kölc9, Ş. A. Bilgen1, G. Durhan2, A. Akoğlu3, M. Aryürek2,3, Haceteppe University, Rheumatology, Ankara, Turkey; Haceteppe University, Internal Medicine, Ankara, Turkey; Haceteppe University, Radiology, Ankara, Turkey

Background: Intestinal lung disease is an important cause of mortality and morbidity for RA. Lung computerized tomography (CT) is a valid method for the detection of intestinal lung disease (ILD) in rheumatoid arthritis (RA) patients. Besides, CT may have a role in the detection of progression in RA-ILD.

Objectives: To compare the clinical and radiological features of RA-ILD patients with and without radiographic progression according to lung CT.

Methods: From the hospital database, all patients recorded as having RA according to ACR-10 code and had a lung CT examination were recruited. RA was confirmed in 822 of 2305 (35.6%) patients. Three radiologists re-evaluated lung CTs and 156/822 (18.9%) patients with had RA-ILD. Of these 156 patients, 101 (64.7%) had at least 1 follow-up long CT and these patients were included to analysis. Demographic and clinical data of the patients were recorded. ILD was divided into 3 main groups by radiologists: Usual interstitial pneumonia (UIP), non-specific interstitial pneumonia (NSIP) and airway disease (AD) (bronchiectasis and/or bronchiolitis without parenchymal involvement). Avila et al reported a grading system to assess the severity of ILD using HRCT (1). In our study we utilized a similar method using interlobular septal thickening, ground glass opacities, reticulations, traction bronchiectasis and honeycomb appearance as elementary findings to evaluate the RA associated ILD. Septal thickening, reticulations and ground glass opacities were considered as relatively mild features whereas traction bronchiectasis and honeycomb appearance were considered as severe findings as those frequently result from advanced fibrosis. The lungs were divided into upper, middle and lower zones with equal number of slices. Progression was defined as involvement of more zones in vertical extent by the same elementary findings or emergence of more severe findings (i.e traction bronchiectasis or honeycomb appearance) in the same zones compared to previous exam. For the multivariate analysis, the possible factors identified with univariate analyses were further entered into the logistic regression analysis to determine independent predictors of radiographic progression.

Results: In this study, 101 patients with 215 lung CT were included to analysis. 67 (66.3%) patients had 3 CTs, 30 (29.9%) patients 4 CTs and 17 (16.9%) patients had 5 CTs. Mean duration between first and last CT was 47.7±38.8 months. Of 101 patients, radiographic progression was seen in 42 (41.6%) patients. Univariate comparison of demographic, clinical and radiographic features of patients with or without radiographic progression were given in Table. In multivariate analysis (adjusted for ILD disease duration) having ground-glass opacity (aOR 8.6; CI: 1.85-44.49; p=0.011), male gender (aOR 2.9; CI: 1.13-7.4; p=0.026) were found as independent risk factors radiographic progression, while taking methotrexate (ever) (aOR 0.21; CI: 0.07-0.6; p=0.04) was found as an independent protector factor for radiographic progression.

Conclusion: The prediction of ILD progression in RA patients was a challenge for clinicians. According to lung CT, baseline ground-glass opacities looks like prominent factor for ILD progression, particularly at male RA patients. Using methotrexate in ILD patients is a dilemma in routine practice, our results demonstrate that methotrexate (not other cs or bDMARDs) is protectice drugs for ILD progression, however these results should be confirmed in the further studies.


DISCLOSURE OF INTERESTS: Umut Kalyoncu Consultant of: Abbvie, Amgen, Janssen, Lilly, Novartis, UCB, Mustafa Ekcii: None declared, Emre Bilgin: None declared, Alper San: None declared, Yusuf Baytar: None declared, Erdутlu Cagri Bolet: None declared, Berkcan Arman: None declared, Bayram Farişoğulları: None declared, Omer Karadag: None declared, Ali İhsan Ertendi: None declared, Sedat Kiraz: None declared, Levent Kölc: None declared, Șule Apräs Bilgen: None declared, Gamze Durhan: None declared, Ali Akoğlu: None declared, Maçit Anyûrek: None declared

DOI: 10.1136/annrheumdis-2020-eular.4699

THE ASSOCIATION BETWEEN OSTEOPOROSIS AND FUNCTIONAL IMPAIRMENT EVALUATED BY THE LOCOMO25 IN RHEUMATOID ARTHRITIS

T. Kashiwagura1, M. Kobayashi2, Y. Sugimura3, T. Kawanou4, H. Sato5, Y. Shimada6,7,8, Akita City Hospital, Department of Orthopedic Surgery, Akita, Japan; 7Hiraka General Hospital, Yokote, Japan; 8Nakadori General Hospital, Department of Orthopedic Surgery, Akita, Japan, 9Akita University Graduate School of Medicine, Akita, Japan, 10Kita Akita Municipal Hospital, Kita, Akita, Japan

Background: Locomotive syndrome is a condition in which activities of daily living are affected by impairment of the motor organs, most often due to rheumatoid arthritis (RA). Locomo25 is a new index developed for the early detection of locomotive syndrome. It consists of 25 items associated with pain, physical activity, and subjective state of health, with a score of 7 points or higher classified as Grade 1 locomotive syndrome and a score of 16 points or higher as Grade 2. In RA, joint impairment causes the appearance of problems affecting major organs as a whole, as well as progressive functional impairment. As functional impairment progresses, it causes increasing immobility, which raises the risk of osteoporosis.

Objectives: Locomo25 was used to investigate functional impairment and its association with RA disease activity and osteoporosis indicators. Methods: The subjects were 105 patients with RA (24 men and 81 women) with a mean age of 68.7 (28–91) years. In terms of staging, 25 were Stage I, 22 Stage II, 17 Stage III, and 41 Stage IV, and their motor disability was Steinbrocker Class 1 in 68 cases, Class 2 in 27, Class 3 in 9, and Class 4 in 1. Disease activity according to the Disease Activity Score 28 with erythrocyte sedimentation rate (DAS28 ESR) was assessed as remission in 44 cases, low disease activity in 24, moderate in 33, and high in 34. The associations between the Locomo25 score and disease activity indices, bone mineral density (BMD), and bone turnover markers (TRACP-5b, NTx, urinary DPD, BAP, total P1NP, and 25(OH)D) were investigated.

Results: Locomo25 grade was 0 in 37 cases (35.2%), 1 in 24 (22.9%), and 2 in 44 (41.9%). Locomo25 grade was significantly associated with Steinbrocker class (r = 0.4299, Spearman’s rank correlation coefficient, p < 0.0001). DAS28 ESR and Health Assessment Questionnaire scores increased as locomotive syndrome progressed. There was no significant difference in eGFR between groups, but bone resorption markers (TRACP-5b, NTx, and urinary DPD) and a bone quality marker (pentosidine) decreased significantly as locomotive syndrome progressed. There were no significant differences in BMD or other bone turnover markers.

Conclusion: The Locomo25 score was useful for evaluating functional impairment in RA. The prevalence of Grade 2 locomotive syndrome in the general population is reported to be around 25%, and many patients with RA had advanced locomotive syndrome. Although there was no significant difference in BMD, elevated bone resorption and deteriorating bone quality were associated with progressive functional impairment, suggesting that RA patients with advanced locomotive syndrome may be at risk of increasingly severe osteoporosis as a result of immobility.
Department of Nursing, Kyoto, Japan; Rheumatic Diseases, Kyoto, Japan; for support of the patients. We also thank Drs. Takao Fujii, Chicashi, Terao, Masahide Hamaguchi, Hiroyuki Yoshitomi, and Masahiro Ishikawa for their thoughtful comments.

Disclosure of Interests: Masao Katsuhashi: None declared, Motomu Hashimoto Grant/research support from: Bristol-Myers Squibb, Eisai, and Eli Lilly and Company., Speakers bureau: Bristol-Myers Squibb and Mitsubishi Tanabe Pharma., Mirei Shirakashi: None declared, Tamami Yoshida: None declared, Wataru Yamamoto: None declared, Kosaku Murakami Speakers bureau: AbbVie, Eisai, and Mitsubishi Tanabe Pharma., Koichi Murata Grant/research support from: KMurata belong to a department that has been financially supported by four pharmaceutical companies (Mitsubishi-Tanabe, Chugai, AYUMI and UCB Japan)., Employee of: KMurata belong to a department that has been financially supported by four pharmaceutical companies (Mitsubishi-Tanabe, Chugai, AYUMI and UCB Japan)., Speakers bureau: KMurak has received speaking fees, and/or consulting fees from Eisai Co. Ltd, Chugai Pharmaceutical Co. Ltd., Pfizer Japan Inc, Bristol-Myers Squibb, Mitsubishi-Tanabe Pharma Corporation, UCB, Daiichi Sankyo Co. Ltd. and Astellas Pharma Inc., Kohei Nishitani Grant/ research support from: KN belong to a department that has been financially supported by four pharmaceutical companies (Mitsubishi-Tanabe, Chugai, AYUMI and UCB Japan)., Masao Tanaka Grant/research support from: AbbVie, Asahi Kasei Pharma, Astellas Pharma, Ayumi Pharmaceutical, Chugai Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Taisha Pharmaceutical, and UCB Japan.

Disclosure of Interests: Koichi Hashimoto Grant/research support from: Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Eli Lilly and Company, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Novartis Pharma, Pfizer, Taisha Pharmaceutical, Takeda Pharmaceutical, and UCB Japan., Hiromu Ito: None declared, Shuichi Matsuda: None declared.


AB0197

Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the Kurama database


Background: Adiponectin is a major adipokine with pleiotropic effects on inflammatory conditions including rheumatoid arthritis (RA). Adiponectin generally has anti-atherogenic effects, and its serum level inversely correlates with body mass index (BMI) and visceral fat area (VFA). On the other hand, several studies have indicated a deleterious role of adiponectin in RA progression [1]. Recently, both low BMI and increased serum adiponectin have been reported as poor prognostic factors of RA [2, 3]. However, large-scale surveys have not been done focusing on both BMI and serum adiponectin, and it is unclear which factor provides further contribution to RA disease activity. In addition, the effects of biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase (JAK) inhibitors on serum adiponectin are largely unknown.

Objectives: To clarify the relationship among serum adiponectin, body composition, current disease activity and therapeutic agents of RA.

Methods: We conducted a cross-sectional study in RA patients under treatment with agents including bDMARDs and JAK inhibitors. A total of 351 subjects from the Kyoto University RA Management Alliance cohort (KURAMA) were enrolled. We classified the participants into five body composition groups (overweight with or without visceral adiposity, normal with or without visceral adiposity, and underweight), according to the cut-off points for obesity and visceral fat used in Japan: BMI, 18.5 kg/m² for underweight, and VFA, 100 cm² for visceral adiposity. Differences of continuous variables among the five groups were assessed by the Steel-Dwass test or one-way analysis of variance (ANOVA). We adopted a multiple standardised linear regression model to analyze effects of serum adiponectin level on DAS28-ESR.

Results: Serum adiponectin levels (20.9±12.5 vs. 14.7±8.4 µg/ml, p < 0.001) and DAS28-ESR (3.0±4.1 vs. 2.6±3.0, p = 0.017) in the overweight group were significantly higher than those in the others. In multiple regression analysis, serum adiponectin level, but not BMI, was positively correlated with DAS28-ESR (estimate = 0.0127, p = 0.0258). Subanalysis also showed that the use of bDMARD or JAK inhibitor did not have an obvious influence on circulating adiponectin.

Conclusion: In the multiple regression analysis we revealed a positive and independent correlation between serum adiponectin and DAS28-ESR in Japanese RA patients. Thus, serum adiponectin is an potential marker reflecting high disease activity of RA regardless of current medications.

References:

AB0198

Smoking and positivity of rheumatoid factor and anti-cyclic citrullinated peptide antibody in the general population

G. Kidoguchi,1 S. Fukui1, T. Naka1, S. Kawara1, H. Ozawa2, Y. Ikeda3, A. Koido4, Y. Obara1, H. Shimizu5, K. Yamaguchi1, H. Tamaki1, M. Okada1, M. Hamaguchi1, H. Yoshitomi3, M. Ishikawa5.

Background: It is well known that rheumatoid arthritis (RA) occurs due to environmental risk factors in addition to genetic risk factors. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACPA) are strongly associated with RA, and these biomarkers could turn to be positive before development of clinical symptoms. While smoking, particularly Brinkman index (BI) is well known as a risk factor for RA and ACPA positivity, it is still unclear whether smoking intensity or smoking duration contribute more to positive RF and ACPA.

Objectives: This study aims to evaluate risk factors for RF and ACPA positivity in the general population. It also describes whether smoking intensity, duration, and BI are significant.

Methods: This is a cross-sectional, observational, single center study. We reviewed the baseline characteristics of the general population who checked RF and ACPA at Preventive Medicine Center in St. Luke's International Hospital Tokyo, Japan from January 2004 to December 2018. The data for basic demographics, dietary habit, smoking intensity, smoking duration, BI, and blood tests including RF and ACPA were extracted. The data was analyzed statistically.

Results: A total of 127472 people who checked RF are included. Of these 127472 people, 64504 (50.6%) are male and the mean age was 44.9 years. RF was positive in 11477 people (9.0%). Among these, 1667 (1.2%) were checked for ACPA, and 21 people (0.2%) had positive ACPA. None of variables demonstrated significant association with RF positivity. In contrast, BI and smoking duration was significantly associated with an increased risk of ACPA positivity (13.3 years vs 7.49 years, p value = 0.023), although the number of cigarettes smoked was not. The smoking duration for 10 years or more was associated with an increased risk of ACPA positivity even after adjusted for age and sex (adjusted hazard ratio: 2.47 [95% confidence interval: 1.04-5.87]; p=0.04).

Conclusion: In this study, no significant risk factor for positive RF was found. Even smoking was not associated with RF positivity. On the other hand, smoking duration, not smoking intensity was significantly associated with an increased risk of ACPA positivity.

References: